Literature DB >> 18544024

HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal.

Geoffrey S Gottlieb1, Stephen E Hawes, Kim G Wong, Dana N Raugi, Habibatou D Agne, Cathy W Critchlow, Nancy B Kiviat, Papa Salif Sow.   

Abstract

Unique viral variants and resistance mutations may occur in the genital tract of HIV-2 ARV-naive infected women. We sequenced and phylogenetically analyzed protease (PR), reverse transcriptase (RT), and envelope (ENV) from PBMC and genital tract samples from four ARV-naive women in Senegal. HIV-2 protease polymorphisms that predict HIV-1 protease inhibitor (PI) resistance were common. Two subjects had protease mutations (T77I and I64V) in genital tract samples that were not found in PBMCs. One subject had the HIV-2 reverse transcriptase M184I mutation in CVL DNA (but not PBMCs) that is known to confer 3TC/FTC resistance in HIV-2. In another subject, the reverse transcriptase A62V mutation was also found in CVL-RNA but not PBMCs. We found no significant difference in ENV variants between PBMCs and the genital tract. HIV-2 RT and PR mutations in the genital tract of ARV-naive females may have implications for transmitted HIV-2 resistance and ARV therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544024      PMCID: PMC2927038          DOI: 10.1089/aid.2008.0015

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

1.  Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

Authors:  B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.

Authors:  Danuta Pieniazek; Mark Rayfield; Dale J Hu; John N Nkengasong; Vincent Soriano; Walid Heneine; Clement Zeh; Simon M Agwale; Charles Wambebe; Liliana Odama; Stefan Z Wiktor
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

3.  A cladistic measure of gene flow inferred from the phylogenies of alleles.

Authors:  M Slatkin; W P Maddison
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

4.  Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Papa Salif Sow; Stephen E Hawes; Ibra Ndoye; Mary Redman; Awa M Coll-Seck; Mame A Faye-Niang; Aissatou Diop; Jane M Kuypers; Cathy W Critchlow; Richard Respess; James I Mullins; Nancy B Kiviat
Journal:  J Infect Dis       Date:  2002-03-19       Impact factor: 5.226

5.  Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso.

Authors:  Jean Ruelle; Mahamoudou Sanou; Hsin-Fu Liu; Anne-Thérèse Vandenbroucke; Armelle Duquenne; Patrick Goubau
Journal:  AIDS Res Hum Retroviruses       Date:  2007-08       Impact factor: 2.205

6.  Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Authors:  Robert A Smith; Geoffrey S Gottlieb; Donovan J Anderson; Crystal L Pyrak; Bradley D Preston
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

7.  Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.

Authors:  K M De Cock; G Adjorlolo; E Ekpini; T Sibailly; J Kouadio; M Maran; K Brattegaard; K M Vetter; R Doorly; H D Gayle
Journal:  JAMA       Date:  1993-11-03       Impact factor: 56.272

8.  Slower heterosexual spread of HIV-2 than HIV-1.

Authors:  P J Kanki; K U Travers; S MBoup; C C Hsieh; R G Marlink; A Gueye-NDiaye; T Siby; I Thior; M Hernandez-Avila; J L Sankalé
Journal:  Lancet       Date:  1994-04-16       Impact factor: 79.321

9.  Cellular and plasma viral load in patients infected with HIV-2.

Authors:  F Simon; S Matheron; C Tamalet; I Loussert-Ajaka; S Bartczak; J M Pépin; C Dhiver; E Gamba; C Elbim; J A Gastaut
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

10.  Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Papa Salif Sow; Stephen E Hawes; Ibra Ndoye; Awa M Coll-Seck; Marcel E Curlin; Cathy W Critchlow; Nancy B Kiviat; James I Mullins
Journal:  AIDS Res Hum Retroviruses       Date:  2003-07       Impact factor: 2.205

View more
  7 in total

1.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

2.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  A Comparison of the Natural History of HPV Infection and Cervical Abnormalities among HIV-Positive and HIV-Negative Women in Senegal, Africa.

Authors:  Hilary K Whitham; Stephen E Hawes; Haitao Chu; J Michael Oakes; Alan R Lifson; Nancy B Kiviat; Papa Salif Sow; Geoffrey S Gottlieb; Selly Ba; Marie P Sy; Shalini L Kulasingam
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-17       Impact factor: 4.254

4.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

5.  Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.

Authors:  Ming Chang; Geoffrey S Gottlieb; Joan A Dragavon; Stephen L Cherne; Donna L Kenney; Stephen E Hawes; Robert A Smith; Nancy B Kiviat; Papa Salif Sow; Robert W Coombs
Journal:  J Clin Virol       Date:  2012-07-24       Impact factor: 3.168

6.  HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Robert A Smith; Ndeye Mery Dia Badiane; Selly Ba; Stephen E Hawes; Macoumba Toure; Alison K Starling; Fatou Traore; Fatima Sall; Stephen L Cherne; Joshua Stern; Kim G Wong; Paul Lu; Moon Kim; Dana N Raugi; Airin Lam; James I Mullins; Nancy B Kiviat
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

Review 7.  Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Authors:  Didier K Ekouevi; Boris K Tchounga; Patrick A Coffie; Joseph Tegbe; Alexandra M Anderson; Geoffrey S Gottlieb; Marco Vitoria; François Dabis; Serge P Eholie
Journal:  BMC Infect Dis       Date:  2014-08-26       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.